Galecto
GLTO
NASDAQ
IPO2020
about GLTO
Galecto is a biopharmaceutical company focused on developing innovative therapies for rare diseases, including its lead product Mogamulizumab for certain blood cancers and other investigational treatments.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $4.59 | $5.02 | $3.81 | $3.80M | 54.11M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$2.60 | n/a | 115.06 | -6842.00% | -6800.00% | 0% |